We serve Chemical Name:(Deamino-Phe19,D-Ala24,D-Pro26-psi(CH2NH)Phe27)-GRP (19-27) (human, porcine, canine) trifluoroacetate salt CAS:142061-53-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(Deamino-Phe19,D-Ala24,D-Pro26-psi(CH2NH)Phe27)-GRP (19-27) (human, porcine, canine) trifluoroacetate salt
CAS.NO:142061-53-8
Synonyms:(deamino-phe6;Deamino-Phe-His-Trp-Ala-Val-D-Ala-His-D-Pro-(@)-Phe-NH2
Molecular Formula:C57H72N14O8
Molecular Weight:1081.27000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:1540.6ºC at 760mmHg
Density:1.299g/cm3
Index of Refraction:1.627
PSA:323.18000
Exact Mass:1080.57000
LogP:4.93110
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (deamino-phe6 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Deamino-Phe-His-Trp-Ala-Val-D-Ala-His-D-Pro-(@)-Phe-NH2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(deamino-phe6 Use and application,Deamino-Phe-His-Trp-Ala-Val-D-Ala-His-D-Pro-(@)-Phe-NH2 technical grade,usp/ep/jp grade.
Related News: Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit Methyl-thiophosphoramidic acid O-(2,2-dichloro-vinyl) ester O’-(3-phenyl-propyl) ester manufacturers As a result, the team identified and prioritized studies that would provide the necessary product and process understanding needed to develop a control strategy, ensure the reproducibility of the product, and meet its intended safety, efficacy, stability, and performance profile regardless of the manufacturing scale. 2-Brom-3-dimethylamino-1-phenyl-prop-2-en-1-on suppliers As currently constituted, Vanamali employs roughly 140 works in Hyderabad, Telangana, that specialize in API starting materials and contract research, according to its website. Wavelength said the Indian firm currently sports enough capacity for research- to commercial-scale production of its drug intermediates. N-((5-chloro-2-methoxy-3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)carbamoyl)-2,6-difluorobenzamide vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit Methyl-thiophosphoramidic acid O-(2,2-dichloro-vinyl) ester O’-(3-phenyl-propyl) ester manufacturers As a result, the team identified and prioritized studies that would provide the necessary product and process understanding needed to develop a control strategy, ensure the reproducibility of the product, and meet its intended safety, efficacy, stability, and performance profile regardless of the manufacturing scale. 2-Brom-3-dimethylamino-1-phenyl-prop-2-en-1-on suppliers As currently constituted, Vanamali employs roughly 140 works in Hyderabad, Telangana, that specialize in API starting materials and contract research, according to its website. Wavelength said the Indian firm currently sports enough capacity for research- to commercial-scale production of its drug intermediates. N-((5-chloro-2-methoxy-3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)carbamoyl)-2,6-difluorobenzamide vendor & factory.
